Physician profile
Jesse V Deleon
NPI 1275553596
$2,638.74
in general payments reported to CMS, 2019-2025
26 companies · $31.58 in 2025
The $31.58 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $200 · 2021: $195 · 2022: $482 · 2023: $370 · 2024: $160 · 2025: $31.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $662.28 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $394.99 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $315.16 | 2019-2023 | Mounjaro |
| Pfizer INC. | $178.85 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $168.59 | 2019-2023 | |
| Corcept Therapeutics | $114.40 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.16 | 2019-2020 | |
| Amgen INC. | $106.46 | 2019-2023 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $65.86 | 2019-2021 | |
| Astellas Pharma US INC | $56.13 | 2019-2024 | Veozah |
| Merck Sharp & Dohme LLC | $55.46 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.89 | 2019 | |
| Glaxosmithkline, LLC. | $48.86 | 2019-2023 | Shingrix |
| Horizon Therapeutics Plc | $38.83 | 2019 | |
| Shire North American Group INC | $35.35 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $35.32 | 2023-2024 | Accrufer |
| Janssen Pharmaceuticals, INC | $30.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.31 | 2019 | |
| Allergan, INC. | $28.47 | 2019 | |
| Exact Sciences Corporation | $18.94 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $18.61 | 2023 | Quviviq |
| Cranial Technologies, INC | $17.61 | 2025 | Doc Band |
| Teva Pharmaceuticals USA, INC. | $15.28 | 2023 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.97 | 2025 | Caplyta |
| Amarin Pharma, INC. | $13.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Deleon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.